440 related articles for article (PubMed ID: 16328318)
1. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
3. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
Kubitza D; Becka M; Zuehlsdorf M; Mueck W
J Clin Pharmacol; 2007 Feb; 47(2):218-26. PubMed ID: 17244773
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.
Zhao X; Sun P; Zhou Y; Liu Y; Zhang H; Mueck W; Kubitza D; Bauer RJ; Zhang H; Cui Y
Br J Clin Pharmacol; 2009 Jul; 68(1):77-88. PubMed ID: 19660005
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.
Kubitza D; Becka M; Roth A; Mueck W
Curr Med Res Opin; 2008 Oct; 24(10):2757-65. PubMed ID: 18715524
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
J Clin Pharmacol; 2006 Sep; 46(9):981-90. PubMed ID: 16920892
[TBL] [Abstract][Full Text] [Related]
7. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.
Mueck W; Becka M; Kubitza D; Voith B; Zuehlsdorf M
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):335-44. PubMed ID: 17595891
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.
Jiang J; Hu Y; Zhang J; Yang J; Mueck W; Kubitza D; Bauer RJ; Meng L; Hu P
Thromb Haemost; 2010 Jan; 103(1):234-41. PubMed ID: 20062915
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Mueck W; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Kälebo P; Muelhofer E; Misselwitz F; Eriksson BI
Thromb Haemost; 2008 Sep; 100(3):453-61. PubMed ID: 18766262
[TBL] [Abstract][Full Text] [Related]
11. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
12. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
Br J Clin Pharmacol; 2007 Apr; 63(4):469-76. PubMed ID: 17100983
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Roth A; Becka M; Alatrach A; Halabi A; Hinrichsen H; Mueck W
Br J Clin Pharmacol; 2013 Jul; 76(1):89-98. PubMed ID: 23294275
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
17. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.
Kubitza D; Becka M; Roth A; Mueck W
J Clin Pharmacol; 2013 Mar; 53(3):249-55. PubMed ID: 23381840
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban: an oral direct inhibitor of factor Xa.
Gulseth MP; Michaud J; Nutescu EA
Am J Health Syst Pharm; 2008 Aug; 65(16):1520-9. PubMed ID: 18693206
[TBL] [Abstract][Full Text] [Related]
19. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
Kubitza D; Becka M; Zuehlsdorf M; Mueck W
J Clin Pharmacol; 2006 May; 46(5):549-58. PubMed ID: 16638738
[TBL] [Abstract][Full Text] [Related]
20. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]